Variations in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe

C Winter, A Macfarlane, C Deneux-Tharaux, W-H Zhang, S Alexander, P Brocklehurst, M-H Bouvier-Colle, W Prendiville, V Cararach, J van Roosmalen, I Berbik, M Klein, D Ayres-de-Campos, R Erkkola, LM Chiechi, J Langhoff-Roos, B Stray-Pedersen, C Troeger

School of Nursing and Midwifery, University of Dundee, Dundee, UK
Department of Midwifery, City University, London, UK
INSERM UMR S149, Université PMC-Paris 6, Paris, France
Perinatal Epidemiology Research Unit, Université Libre de Bruxelles, Brussels, Belgium
National Perinatal Epidemiology Unit, Oxford, UK
Department of Obstetrics and Gynaecology, Royal College of Surgeons of Ireland, Coombe Hospital, Dublin, Ireland
Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Leiden University Medical Centre, Leiden, the Netherlands
Hungarian Society of Obstetrics and Gynaecology, Budapest, Hungary
Hanusch-Krankenhaus Gynaikolog, University of Vienna, Vienna, Austria
Faculdade de Medicina da Universidade do Porto, Porto, Portugal
University Central Hospital of Turku, Turku, Finland
Unita di Obstetrica e gynecologia policlinica, University of Bari, Bari, Italy
Department of Obstetrics and Gynaecology, University of Copenhagen, Copenhagen, Denmark
Rikshospitalet, University of Oslo, Oslo, Norway
Pränatale Medizin, Universität Frauenklinik, Basel, Switzerland

Correspondence: Prof A Macfarlane, Department of Midwifery, City University, 24 Chiswell Street, London EC1Y 4TY, UK.
Email A.J.Macfarlane@city.ac.uk

Accepted 26 March 2007.

Background The European Project on obstetric Haemorrhage Reduction: Attitudes, Trial, and Early warning System (EUPHRATES) is a set of five linked projects, the first component of which was a survey of policies for management of the third stage of labour and immediate management of postpartum haemorrhage following vaginal birth in Europe.

Objectives The objectives were to ascertain and compare policies for management of the third stage of labour and immediate management of postpartum haemorrhage in maternity units in Europe following vaginal birth.

Design Survey of policies.

Setting The project was a European collaboration, with participants in 14 European countries.

Sample All maternity units in 12 countries and in selected regions of two countries in Europe.

Methods A postal questionnaire was sent to all or a defined sample of maternity units in each participating country.

Main outcome measures Stated policies for management of the third stage of labour and the immediate management of postpartum haemorrhage.

Results Policies of using uterotonics for the management of the third stage were widespread, but policies about agents, timing, clamping and cutting the umbilical cord and the use of controlled cord traction differed widely. For immediate management of postpartum haemorrhage, policies of massaging the uterus were widespread. Policies of catheterising the bladder, bimanual compression and in the choice of drugs administered were much more variable.

Conclusions Considerable variations were observed between and within countries in policies for management of the third stage of labour. Variations were observed, but to a lesser extent, in policies for the immediate management of postpartum haemorrhage after vaginal birth. In both cases, policies about the pharmacological agents to be used varied widely.

Keywords Management policies, obstetric emergencies, postpartum haemorrhage, third stage of labour.
**Introduction**

Despite the overall decline in maternal mortality in high-income countries, including those in Europe, since the middle of the 20th century, postpartum haemorrhage still makes a major contribution to maternal mortality and severe maternal morbidity in Europe.1–3

A collaborative project in the mid-1990s showed that there were wide differences between rates of severe pre-eclampsia, sepsis and postpartum haemorrhage in participating European countries, even though common definitions were used to collect the data.1 In this survey, overall differences between countries were dominated by differences in the incidence of postpartum haemorrhage. This ranged from 8.8 per 1000 deliveries in Finland to 0.7 in Austria. Possible explanations included differences in ascertainment,1 differences in the age distribution of women giving birth2 and differences in the ways in which care is provided and its quality.4

There is a prevailing view that the quality of care is particularly crucial where postpartum haemorrhage is concerned and that substandard care contributes to differences in the incidence of postpartum haemorrhage. Therefore, the adoption of appropriate policies, the availability of sufficient resources and the deployment of these resources to provide good care are central to the reduction of rates of severe postpartum haemorrhage.4 Despite this, little is known about relevant policies or practices in Europe. In response to these concerns, the five-part EUropean Project on obstetric Haemorrhage Reduction: Attitudes, Trial, and Early Warning System (EUPHRATES) was undertaken to address issues related to the prevention and management of postpartum haemorrhage.

The first component of this project was a survey undertaken to describe current obstetric and midwifery policies related to the prevention and management of postpartum haemorrhage in 14 countries of Europe and to inform the second part of the project, the development of a minimal European consensus for good practice related to the prevention and management of obstetric postpartum haemorrhage.5 The survey covered hospital policies in all the 14 countries and home birth policies in two of them. This article describes the methods used and the key findings about policies for the management of the third stage of labour and the immediate management of severe postpartum haemorrhage after vaginal birth in hospital and compares them with the available evidence.

**Methods**

The project was a European collaboration, with participants from 12 European Union member states, Austria, Belgium, Denmark, Finland, France, Hungary, Ireland, Italy, the Netherlands, Portugal, Spain, and the UK plus Norway and Switzerland. Most countries sent a questionnaire to all their maternity units. The exceptions were Spain, where the survey covered maternity units in Catalonia; Portugal, where private maternity units were not surveyed; and France, where a purposive sample of six regions, reflecting a range of measures of maternal health and diversity of maternity care provision, was selected from regions willing to participate. Country coordinators were asked to provide available information about the units surveyed to enable the investigation of possible response bias in countries with low response rates.

A postal questionnaire was designed by the study steering group and refined and piloted by each participating country. It was sent out in 2003 and included questions about definition of postpartum haemorrhage, policies for management of the third stage of labour in vaginal birth and caesarean section, measurement of blood loss and management of postpartum haemorrhage. In each case, respondents were asked whether the policy in their unit was to use the specified interventions usually, occasionally, sometimes or never. In addition, questions were asked about the resources available in each maternity unit and about the level of activity in the preceding year, 2002.

The questionnaire was initially developed in English, and collaborators in each country decided whether translation into local languages would be beneficial. As a result, collaborators in France, Hungary, Norway, Portugal, Italy and Spain translated the questionnaire into their own languages. In Spain, where the survey was undertaken in Catalonia, the questionnaire was translated into both Catalan and Spanish languages, giving respondents a choice of language in which to reply. Because of the highly technical nature of the questions, formal back translation was not undertaken, but the questionnaires were checked against the English original.

Coordinators in each participating country established or obtained a list of maternity units to be surveyed. One questionnaire was sent to each unit, addressed to the midwife or obstetrician with overall management responsibility. Details are shown in Table 1. Two reminders were sent to non-respondents, and additional prompts were given in some countries. The questionnaires were returned to coordinators within the country and then forwarded to City University, London, where data were entered onto an Access database and checks for inconsistency were undertaken. If any issues in the questionnaires needed clarification, the country coordinators were contacted for an explanation. The data were then analysed using the Statistical Package for the Social Sciences, version 12.0 for Windows (SPSS Inc., Chicago, IL, USA).

This article describes the replies to five questions about the management of the third stage of labour and five questions about the immediate management of postpartum haemorrhage following vaginal birth.

The third stage of labour is defined as the period from birth of the baby until the placenta and its membranes are expelled. A sequence of procedures, known as ‘active management’, has been developed, but there is considerable variation in how these policies are defined and practised. As part of its consensus development process, the EUPHRATES group defined
**Table 1. Samples and response rates**

| Country | Maternity units sampled | Language | Number of units surveyed | Number of questionnaires received | Response rate (%) |
|---------|-------------------------|----------|--------------------------|----------------------------------|-------------------|
| Austria | All                     | English  | 104                      | 33                               | 31.7              |
| Belgium | All                     | English  | 129                      | 105                              | 81.4              |
| Denmark | All                     | English  | 29                       | 23                               | 79.3              |
| Finland | All                     | English  | 33                       | 33                               | 100.0             |
| France  | Six regions             | French   | 132                      | 109                              | 82.6              |
| Hungary | All                     | Hungarian| 98                       | 98                               | 100.0             |
| Ireland | All                     | English  | 22                       | 22                               | 100.0             |
| Italy   | All                     | Italian  | 719                      | 215                              | 29.9              |
| Netherlands | All                   | English  | 99                       | 91                               | 91.9              |
| Norway  | All                     | Norwegian| 55                      | 46                               | 83.6              |
| Portugal| All public maternity units | Portuguese | 52               | 37                               | 71.2              |
| Spain   | Catalonia               | Catalan and Spanish | 62          | 53                               | 85.5              |
| Switzerland | All               | English  | 130                      | 68                               | 52.3              |
| UK      | All                     | English  | 354                      | 242                              | 68.4              |

‘active management’ as an intervention with the following three components:

1. Prophylactic administration of a uterotonic agent.
2. Clamping and cutting the cord immediately after birth or after it has stopped pulsating.
3. Controlled cord traction to aid the delivery of the placenta.

The analysis first looked separately at each component of active management and then at the extent to which responding units said that they used them all.

The questions about management of the third stage asked about policies for clamping and cutting the umbilical cord, draining the placenta, controlled cord traction and the prophylactic use of uterotonics, including their type and the timing of administration. In each case, the question asked whether the practice was used ‘usually’, ‘sometimes’, ‘rarely’ or ‘never’. If there was no reply to the question, this was interpreted as implying that there was no policy about using the practice.

Tables 2–4 are based on numbers of units in which the various interventions were said to be used ‘usually’, as this was assumed to imply either formally adopted or informally accepted policies. Where respondents replied ‘usually’ to two apparently mutually exclusive practices, this was tabulated separately.

The questions about the immediate management also asked whether the practices were used ‘usually’, ‘sometimes’, ‘rarely’ or ‘never’ and were analysed in the same way. The questions about use of pharmacological or other agents for the immediate management of haemorrhage asked respondents to name the agent which would be used first and which would be used next if bleeding continued.

The responses were compared using both asymptotic and Monte Carlo estimates of Pearson’s chi-square, calculated using StatXact.7 (Cytel Inc., Cambridge, MA, USA). The results were compared with the evidence available from Cochrane reviews, summarised in Figure 1.

**Role of the funding source**

The project was funded by the European Union under Framework 5. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or the writing of the report. The steering group had full access to all the data in the study and had final responsibility for submission for publication on behalf of the EUPHRATES Group.

**Results**

**Response rates and investigation of response bias**

The number of questionnaires sent out ranged from 22 in Ireland to 719 in Italy. This wide range resulted from differences in the overall numbers of births and in the sizes of maternity units in the participating countries. Response rates varied from 29.9% in Italy and 31.7% in Austria to 100% in Hungary, Finland and Ireland, with response rates above 65% in 11 out of 14 countries, as Table 1 shows, with only Austria, Italy and Switzerland having rates below this level. In Italy, response rates in public and private hospitals were similar. Among public hospitals, for which fuller information was available, there was considerable regional variation, with rates around 50% in the regions of Lombardia, Veneto and Friuli-Venezia Giulia. Elsewhere, response rates ranged from zero among the nine maternity units in Umbria to around 40% in the regions of Puglia and Basilicata. In Switzerland, response rates were higher from the public sector than from the private sector, with only a few private hospitals replying. No information was available to investigate possible response bias in Austria.
In the statistical tests undertaken on the data in Tables 1–5, P values were below 0.0005 in each case, demonstrating wide differences in policies between the participating countries.

Managing the third stage of labour

**Cutting and clamping the cord and draining the placenta**

Maternity units were asked about the point at which the cord was clamped and cut. Table 2 shows that between 66 and 90% of units in Belgium, France, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland and the UK had policies of clamping and cutting the cord immediately after the birth, but between 65 and 74% of units in Austria, Denmark, Finland, Hungary and Norway had policies of waiting until the cord stopped pulsating. More than 10% of units in Austria, Hungary, Italy and Switzerland did not give a stated policy. Five units, three in the UK, one in Spain and one in Norway, said they usually cut the cord at both times and were included in those with no stated policies.

Replies to the question about draining the placenta, which is not seen as part of ‘active management’, suggested that this practice was not widespread in any country, except in Belgium, where it was policy in 32% of maternity units, and Portugal, where it was a policy in 24%. Apart from this, it was policy in approximately 14% of units in Ireland, 15% of units in Norway and Spain and between 0 and 7% in the other countries, as Table 2 shows.

**Controlled cord traction**

Policies of controlled cord traction were also common, but their extent differed markedly between countries. Controlled cord traction was policy in 87% of units in the UK, in 95% of those in Ireland and from 39 to 51% of units in Belgium, the Netherlands, Norway, Portugal and Switzerland. In the other participating countries, it was said to be policy in between 12 and 25% of units.

**Prophylactic use of uterotonics**

It was policy to use uterotonics prophylactically in between 72 and 100% of units in most participating countries apart from Austria and Denmark where 55 and 57% of the units, respectively, reported a policy of using them, as Table 2 shows.

Policies for the timing of prophylactic administration of uterotonic agents diverged considerably, as Table 3 shows. In the 68% of units in the UK and Ireland, it was policy to administer them immediately after the delivery of the anterior shoulder, while between 62 and 87% of units in Denmark, Finland, the Netherlands, Norway and Switzerland favoured administering uterotonics immediately after birth. Between 69 and 77% of units in Italy, Portugal and Spain had policies of administering them after the delivery of the placenta. In Belgium, France and Hungary, policies differed both between and within units. In particular, 10% of units in Belgium and 19% in France cited more than one policy. It is possible that, in these units, two doses of uterotonic are administered at

---

Table 2. Policies for management of the third stage of labour after vaginal birth in maternity units from 14 European countries

| All units replying, n | Timing of cutting and clamping cord | Controlled cord traction, n (%) | Administration of prophylactic uterotonics, n (%) | Active management, n (%) | Draining the placenta, n (%) |
|-----------------------|-------------------------------------|--------------------------------|-----------------------------------------------|------------------------|-----------------------------|
|                       | Immediately after birth, n (%)      | After the cord stops pulsating, n (%) | Other and not stated,* n (%) |                         |                             |
| Austria 33            | 5 (15)                             | 23 (70)                        | 5 (15)                                       | 7 (21)                 | 18 (55)                     | 1 (3)                       | 1 (3)                       |
| Belgium 105           | 92 (88)                            | 11 (10)                        | 2 (2)                                        | 45 (43)                | 93 (89)                     | 36 (34)                     | 34 (32)                     |
| Denmark 23            | 4 (17)                             | 17 (74)                        | 2 (9)                                        | 5 (22)                 | 13 (57)                     | 2 (9)                       | 1 (4)                       |
| Finland 33            | 9 (27)                             | 23 (70)                        | 1 (3)                                        | 7 (21)                 | 29 (88)                     | 4 (12)                      | 2 (6)                       |
| France 109            | 98 (90)                            | 7 (6)                          | 4 (4)                                        | 24 (22)                | 104 (95)                    | 22 (20)                     | 7 (6)                       |
| Hungary 98            | 20 (20)                            | 66 (67)                        | 12 (12)                                      | 12 (12)                | 89 (91)                     | 5 (5)                       | 3 (3)                       |
| Ireland 22            | 16 (73)                            | 5 (23)                         | 1 (5)                                        | 21 (95)                | 22 (100)                    | 17 (77)                     | 3 (14)                      |
| Italy 215             | 142 (66)                           | 43 (20)                        | 30 (14)                                      | 28 (13)                | 197 (92)                    | 20 (9)                      | 14 (7)                      |
| Netherlands 91        | 67 (74)                            | 21 (23)                        | 3 (3)                                        | 41 (45)                | 86 (95)                     | 33 (36)                     | 0 (0)                       |
| Norway 46             | 11 (24)                            | 30 (65)                        | 5 (11)                                       | 18 (39)                | 33 (72)                     | 5 (11)                      | 7 (15)                      |
| Portugal 37           | 33 (89)                            | 1 (3)                          | 3 (8)                                        | 19 (51)                | 31 (84)                     | 13 (35)                     | 9 (24)                      |
| Spain 53              | 40 (75)                            | 7 (13)                         | 5 (11)                                       | 13 (25)                | 45 (85)                     | 7 (13)                      | 8 (15)                      |
| Switzerland 68        | 47 (69)                            | 10 (15)                        | 11 (16)                                      | 31 (46)                | 60 (88)                     | 25 (37)                     | 2 (3)                       |
| UK 242               | 186 (77)                           | 31 (13)                        | 25 (10)                                      | 210 (87)               | 232 (96)                    | 182 (75)                    | 8 (3)                       |

* A few units had more than one ‘usual’ policy or had a policy of cutting the cord ‘at another time’.

** Usually cut the cord immediately after birth or after the cord stops pulsating, perform ‘controlled cord traction’ and administer prophylactic uterotonics.
### Table 3. Policies on type and timing of administration of prophylactic uterotonics in vaginal birth in maternity units from 14 European countries

| Country | All units using prophylactic uterotonics, n | Type of prophylactic uterotonics* | Timing of prophylactic uterotonic administration** |
|---------|--------------------------------------------|-----------------------------------|----------------------------------------------------|
|         | Oxytocin alone, n (%) | Syntometrine alone, n (%) | Ergometrine alone, n (%) | More than one ‘usual’, n (%) | Not stated, n (%) | After delivery of the anterior shoulder, n (%) | Immediately after birth, n (%) | After delivery of placenta, n (%) | More than one ‘usual’ time given, n (%) | No time given, n (%) |
| Austria | 18 | 10 (56) | 1 (6) | 0 (0) | 4 (22) | 3 (17) | 4 (22) | 4 (22) | 0 (0) | 1 (6) | 9 (50) |
| Belgium | 93 | 49 (53) | 0 (0) | 24 (26) | 13 (14) | 7 (8) | 23 (25) | 26 (28) | 28 (30) | 9 (10) | 5 (5) |
| Denmark | 13 | 10 (77) | 1 (8) | 0 (0) | 1 (8) | 1 (8) | 1 (8) | 8 (62) | 3 (23) | 0 (0) | 1 (8) |
| Finland | 29 | 18 (62) | 0 (0) | 4 (14) | 7 (24) | 0 (0) | 0 (0) | 24 (83) | 1 (3) | 1 (3) | 1 (3) |
| France | 104 | 96 (92) | 0 (0) | 0 (0) | 1 (1) | 7 (7) | 32 (31) | 9 (9) | 31 (30) | 20 (19) | 11 (11) |
| Hungary | 89 | 64 (72) | 0 (0) | 0 (0) | 11 (12) | 14 (16) | 2 (2) | 45 (51) | 17 (19) | 4 (4) | 21 (24) |
| Ireland | 22 | 4 (18) | 14 (64) | 0 (0) | 2 (9) | 1 (5) | 15 (68) | 6 (27) | 0 (0) | 0 (0) | 1 (5) |
| Italy | 197 | 72 (37) | 7 (4)*** | 34 (17) | 68 (35) | 16 (8) | 6 (3) | 22 (11) | 150 (76) | 5 (3) | 14 (7) |
| Netherlands | 86 | 78 (91) | 0 (0) | 1 (1) | 4 (5) | 3 (3) | 3 (3) | 75 (87) | 3 (3) | 2 (2) | 3 (3) |
| Norway | 33 | 30 (91) | 0 (0) | 0 (0) | 0 (0) | 2 (6) | 0 (0) | 23 (70) | 6 (18) | 0 (0) | 3 (9) |
| Portugal | 31 | 29 (94) | 0 (0) | 0 (0) | 1 (3) | 1 (3) | 1 (3) | 0 (0) | 24 (77) | 1 (3) | 5 (16) |
| Spain | 45 | 41 (91) | 0 (0) | 0 (0) | 1 (2) | 3 (7) | 4 (9) | 3 (7) | 31 (69) | 4 (9) | 3 (7) |
| Switzerland | 60 | 56 (93) | 0 (0) | 0 (0) | 2 (3) | 2 (3) | 7 (12) | 49 (82) | 1 (2) | 2 (3) | 1 (2) |
| UK | 232 | 12 (5) | 201 (87) | 1 (0) | 8 (3) | 9 (4) | 158 (68) | 59 (25) | 2 (1) | 2 (1) | 11 (5) |

*Total is not always 100% because in a few units, an ‘other type’ of prophylactic uterotonic was used.

**Total is not always 100% because in a few units, prophylactic uterotonic were administered ‘at another time’.

***Syntometrine is not available in Italy. One unit had used it experimentally. The others had used combinations of oxytocin and ergometrine separately.
different stages, with the first dose being administered either at the delivery of the anterior shoulder or immediately after the birth and the second after the expulsion of the placenta.

In units with a policy of administering prophylactic uterotonic agents, the agent most commonly used was oxytocin alone. This was used in more than 90% of units in France, the Netherlands, Norway, Portugal, Spain and Switzerland. The exception was in the UK and Ireland, where Syntometrine®, a fixed combination of oxytocin and ergometrine, was used in 87 and 64% of units, respectively. This formulation is not licensed for use in any other participating countries, possibly from Austria. Of the seven units in Italy reporting using it, one had used it experimentally and the others had used combinations of oxytocin and ergometrine separately. This also could have been the case in the units in Denmark and Austria, which reported using it prophylactically.

Much smaller proportions of units, ranging from 14 to 26%, in Belgium, Finland and Italy had policies of using only ergometrine. In addition, in these countries plus Hungary and Austria, between 12 and 35% of units said they used more than one type of prophylactic uterotonics, the usual combination being oxytocin and ergometrine. In France, the coordinator reported that some of these replies arise from policies of using ergometrine after the placenta is delivered, having used oxytocin at an earlier stage.

**Active management**

The proportions of units with policies of using the full package of active management of the third stage of labour described earlier were much lower. While 77% of units in Ireland and 75% of those in the UK had a set of policies which fitted the definition of active management, only 34–37% of units in Belgium, the Netherlands, Portugal and Switzerland and fewer than 20% of those in the other participating countries had policies of active management, as Table 2 shows. It this case, units which answered ‘usually’ to both timings for cutting and clamping the cord were included.

**Procedures for immediate management of postpartum haemorrhage**

From 82 to 100% of units in every country had a policy of massaging the uterus on occasions when postpartum haemorrhage occurs, as Table 4 shows. The proportion of units in each country which had a policy of catheterising the bladder was 80% or more in Austria, France, Hungary, Ireland, the Netherlands and the UK. It ranged from 55 to 75% in Belgium, Italy, Norway, Portugal, Spain and Switzerland. In contrast, only 39% of units in Denmark and 27% in Finland reported this policy. Between 34 and 68% of units in all countries had policies of using bimanual compression of the uterus. The exceptions were in the Netherlands and Italy, where only 15 and 21% of maternity units, respectively, reported this policy.

There was similar diversity in the drug of second choice, should the postpartum haemorrhage not be controlled with the first. In Belgium, France, Hungary, Italy, the Netherlands and Portugal, prostaglandins were the agent of second choice in 50–80% of units. Ergometrine alone was the second choice in more than two-fifths of units in Austria and Spain. Only units in the UK and Ireland gave oxytocin alone as their second choice. This was the case for 46% of units in the UK and 32% of those in Ireland. Only 306 units, just more than one-quarter, specified a third choice of drug, and 259 of these specified either injectable prostaglandins or misoprostol.

**Administration of pharmacological agents**

There were considerable differences both between and within countries in their choice of drugs for the immediate management of postpartum haemorrhage. The proportion of all units using oxytocin alone as their first choice ranged from 28% in the UK to 95% in Portugal. This included 80–95% of the units in France, Hungary, Italy, Norway and Portugal, as Table 5 shows. Syntometrine® was used as a drug of first choice in 18% of units in the UK and 41% of those in Ireland but was used in only one unit in each of Austria, Finland and Switzerland. As Syntometrine® is not licensed for use in these countries, possibly except in Austria, it could be that these units had a policy of using oxytocin and ergometrine in combination. Slightly more than 40% of the units in UK and Spain reported using ergometrine alone as first line management. About one-fifth of units in Austria, Belgium and the Netherlands had policies of using injectable prostaglandins, while 22% of units in Denmark, 18% of those in Finland and 15% in France had a policy of using misoprostol.

| Country | All units replying, n | Massage the uterus, n (%) | Catheterise the bladder, n (%) | Bimanual compression of uterus, n (%) |
|---------|----------------------|---------------------------|-------------------------------|-------------------------------------|
| Austria | 33                   | 29 (88)                   | 27 (82)                       | 16 (48)                             |
| Belgium | 105                  | 100 (95)                  | 79 (75)                       | 44 (42)                             |
| Denmark | 23                   | 22 (96)                   | 9 (39)                        | 13 (57)                             |
| Finland | 33                   | 30 (91)                   | 9 (27)                        | 14 (42)                             |
| France  | 109                  | 98 (90)                   | 87 (80)                       | 40 (37)                             |
| Hungary | 98                   | 82 (84)                   | 82 (84)                       | 35 (36)                             |
| Ireland | 22                   | 22 (100)                  | 21 (95)                       | 8 (36)                              |
| Italy   | 215                  | 201 (93)                  | 118 (55)                      | 45 (21)                             |
| Netherlands | 91            | 75 (82)                   | 84 (92)                       | 14 (15)                             |
| Norway  | 46                   | 42 (91)                   | 29 (63)                       | 21 (46)                             |
| Portugal | 37               | 37 (100)                  | 26 (70)                       | 25 (68)                             |
| Spain   | 53                   | 52 (98)                   | 36 (68)                       | 21 (40)                             |
| Switzerland | 68         | 58 (85)                   | 49 (72)                       | 31 (46)                             |
| UK      | 242                  | 229 (95)                  | 229 (95)                      | 82 (34)                             |
Draining the placenta

Packages for the active management of third stage of labour which did and did not include placental cord drainage

| Main comparison | Reference number | Number of women | Study type | Results |
|-----------------|------------------|-----------------|------------|---------|
| Active management as a package compared with expectant management | 6 | 6477 women | Cochrane review of five randomised trials, four of good quality | Active management of the third stage of labour was more effective in reducing blood loss after birth than expectant management, using none of these. |

Prophylactic uterotonics

Prophylactic ergometrine–oxytocin compared with prophylactic oxytocin

| Main comparison | Reference number | Number of women | Study type | Results |
|-----------------|------------------|-----------------|------------|---------|
| A. Comparison of oxytocin with no uterotonic | 7 | 9332 women | Cochrane review of six randomised trials. | Ergometrine–oxytocin appears to be associated with a small but statistically significant reduction in the risk of postpartum haemorrhage when compared with oxytocin for blood loss of 500 ml or more. No statistically significant difference was observed between the groups for blood loss of 1000 ml or more. Ergometrine–oxytocin was more likely to carry adverse effects for the mother compared with oxytocin. |
| B. Comparison of oxytocin with ergot alkaloids | 8 | Over 3000 pregnant women anticipating a vaginal delivery where oxytocin was given prophylactically for the third stage of labour. | Cochrane review of 14 randomised or quasi-randomised controlled trials. | Oxytocin appears to be beneficial for the prevention of postpartum haemorrhage. There is insufficient information about other outcomes and adverse effects so it is difficult to be confident about the trade-offs for these benefits. There seems little evidence in favour of ergot alkaloids alone compared with either oxytocin alone or with ergometrine–oxytocin, but the data are sparse. |
| C. Comparison of oxytocin plus ergometrine with ergot alkaloids | 9 | 34203 women | Cochrane review of 24 trials of misoprostol and 8 trials of intramuscular prostaglandin | Neither intramuscular prostaglandins nor misoprostol are preferable to conventional injectable uterotonics as part of the active management of the third stage of labour especially for low-risk women. |

Immediate management of haemorrhage

| Main comparison | Reference number | Number of women | Study type | Results |
|-----------------|------------------|-----------------|------------|---------|
| Massaging the uterus | None, apart from physiological observation of effect | | | |
| Catheterising the bladder | None, apart from weak physiological observation | | | |
| Bimanual compression | None, apart from weak physiological observation | | | |
| Drugs of first and second choice | 14 | 64 women with postpartum haemorrhage over 500 ml in two centres. | Cochrane review but only one eligible trial | Rectal misoprostol in a dose of 800 micrograms could be a useful 'first line' drug for the treatment of primary postpartum haemorrhage but more research is needed. |

Clamping the cord

Early cord clamping with late cord clamping

| Main comparison | Reference number | Number of women | Study type | Results |
|-----------------|------------------|-----------------|------------|---------|
| Administration of prophylactic oxytocin before and after delivery of the placenta | 11 | 51 women with singleton pregnancies | Double-blinded randomised trial | Postpartum haemorrhage was less frequent when oxytocin administration was delayed until after placenta delivery. |
| Administration of prophylactic oxytocin before and after delivery of the placenta | 12 | 1486 women | Randomised trial | The administration of prophylactic oxytocin before placental delivery does not reduce the incidence of postpartum haemorrhage or third-stage duration, when compared with giving oxytocin after placental delivery. The incidence of retained placenta was similar in both groups. |

Timing of prophylactic oxytocin administration

| Main comparison | Reference number | Number of women | Study type | Results |
|-----------------|------------------|-----------------|------------|---------|

Draining the placenta

| Main comparison | Reference number | Number of women | Study type | Results |
|-----------------|------------------|-----------------|------------|---------|

Figure 1. Summary of Cochrane reviews and other evidence.
Discussion

This survey showed considerable differences both between countries and between maternity units within European countries in their stated policies for management of the third stage of labour and the immediate management of postpartum haemorrhage. Countries were used as sampling units, both for administrative reasons and also because it was thought that national professional organisations would be likely to issue guidelines and policy recommendations to their members. In fact, only Hungary, the Netherlands, Norway, Spain and Scotland had guidelines on the subject at the time the survey was undertaken, although guidelines have been published subsequently in Denmark and France. The status and influence of these guidelines and the professional and other organisations issuing them is known to vary between countries. For these reasons, one of the components of this project was the development of a consensus statement.5

Because the study included countries where collaborators could be readily identified, it covered 11 of the member states of the European Union at the time it was undertaken; Hungary, which has subsequently joined, plus two nonmembers, Switzerland and Norway. In most countries, all maternity units were surveyed. The exceptions were France, Portugal and Spain. In Portugal, private hospitals were not surveyed because they usually only rent out facilities for deliveries and have no hospital policies on clinical issues. These represented about 5.5% of births in the country at the time the survey was carried out. In France, six regions, containing about 20% of units in France, were surveyed. They were purposively selected to be representative of different parts of the country. The units in these regions were compared to all units in France using data from the 2003 National Perinatal Survey and found to be representative in terms of unit size and level of care and status as university, other public or private units. In Spain, the coordinator chose, for administrative convenience, to survey all units in Catalonia. Two countries had exceptionally low response rates, Italy where, because of illness on the part of the coordinator, reminders were not sent out, and Austria.

It has been shown that many maternity units in most countries do not use the full package of active management but do use some of its components. Most have policies about cutting and clamping the cord, either immediately after the birth or as soon as the cord stops pulsating, but differences in policies about controlled cord traction are much wider. Policies of using uterotonics are very widespread, and differences again relate to the timing of administration together with the pharmacological agent used.

At first sight, the information in Figure 1 suggests that Cochrane reviews provide clear evidence about the active management of the third stage of labour, but closer examination raises a number of questions. Much of the debate and research about the management of the third stage of labour is based on an assumed dichotomy between ‘active’ and ‘expectant’ management. Definitions of active management usually imply a combination of the use of uterotonics, early cord clamping and active efforts to deliver the placenta following delivery, but the definition is neither unambiguous nor agreed in practice.9

A particularly striking difference was in policies about use of uterotonics. While in the UK and the Irish Republic most units had a policy of using Syntometrine, it appears that it was not available in any of the other participating countries. There may be a number of reasons for this. For example, Belgium and Spain have policies of not licensing products

### Table 5. Drug of first choice for management of postpartum haemorrhage in maternity units from 14 European countries

| Country     | All units replying, n | Oxytocin, n (%) | Syntometrine, n (%) | Ergometrine, n (%) | Injectable prostaglandins, n (%) | Misoprostol, n (%) | Other and not stated, n (%) |
|-------------|-----------------------|----------------|--------------------|-------------------|---------------------------------|------------------|-----------------------------|
| Austria     | 33                    | 23 (70)        | 1 (3)              | 3 (9)             | 6 (18)                          | 0 (0)            | 0 (0)                       |
| Belgium     | 105                   | 56 (53)        | 0 (0)              | 29 (28)           | 18 (18)                         | 0 (0)            | 0 (0)                       |
| Denmark     | 23                    | 17 (74)        | 0 (0)              | 1 (4)             | 0 (0)                           | 5 (22)           | 0 (0)                       |
| Finland     | 33                    | 24 (73)        | 1 (3)              | 1 (3)             | 1 (3)                           | 6 (18)           | 0 (0)                       |
| France      | 109                   | 87 (80)        | 0 (0)              | 1 (1)             | 4 (4)                           | 16 (15)          | 1 (1)                       |
| Hungary     | 98                    | 80 (82)        | 0 (0)              | 6 (6)             | 11 (11)                         | 1 (1)            | 0 (0)                       |
| Ireland     | 22                    | 10 (45)        | 9 (41)             | 2 (9)             | 0 (0)                           | 1 (5)            | 0 (0)                       |
| Italy       | 215                   | 172 (80)       | 0 (0)              | 21 (10)           | 10 (5)                          | 9 (4)            | 2 (1)                       |
| Netherlands | 91                    | 51 (56)        | 0 (0)              | 19 (21)           | 19 (21)                         | 2 (2)            | 0 (0)                       |
| Norway      | 46                    | 39 (85)        | 0 (0)              | 2 (4)             | 1 (2)                           | 4 (9)            | 0 (0)                       |
| Portugal    | 37                    | 35 (95)        | 0 (0)              | 1 (3)             | 0 (0)                           | 1 (3)            | 0 (0)                       |
| Spain       | 53                    | 29 (55)        | 0 (0)              | 23 (43)           | 1 (2)                           | 0 (0)            | 0 (0)                       |
| Switzerland | 68                    | 41 (60)        | 1 (1)              | 13 (19)           | 4 (6)                           | 8 (12)           | 1 (1)                       |
| UK          | 242                   | 68 (28)        | 44 (18)            | 102 (42)          | 16 (7)                          | 3 (1)            | 9 (4)                       |
which contain two compounds. As oxytocin and ergometrine are both available, then it could be argued that Syntometrine is unnecessary. In addition, the relevant Cochrane review clearly states that there are more unpleasant adverse effects with Syntometrine than with oxytocin. So this might make some countries reluctant to license Syntometrine.

Although there have been a considerable number of randomised trials of care in the third stage of labour, most have either compared the various pharmacological agents used or compared expectant with active management as a whole. Very few studies have attempted to examine the relative contribution of the individual components of active management. The policy of draining the placenta is not widespread but has been the subject of a Cochrane review, which identified only four trials, two of which were excluded on the grounds of inadequate reporting. Thus, there are still major gaps in the evidence about the optimal management of the third stage.

The survey showed similarities in policies for the immediate management of postpartum haemorrhage but considerable differences in the choice of pharmacological agents. Variation in policies for the management of postpartum haemorrhage was also found in a survey of maternity units conducted in 2000–01 in the UK. Evidence about management of postpartum haemorrhage is extremely sparse. No research has been carried out to establish the usefulness or efficacy of mechanical methods for the management of postpartum haemorrhage caused by uterine atony, let alone about postpartum haemorrhage resulting from tears or ruptures. Bimanual compression of the uterus tends to be used in environments, such as a home birth, where there is no medical support. It maintains homeostasis until the arrival of medical help. A Cochrane review of drugs for immediate management of postpartum haemorrhage identified just one small trial which suggested that rectal misoprostol could be a useful first line treatment but that further trials were needed.

Since this survey was undertaken, a number of trials of use of misoprostol, both for the third stage of labour and for the immediate management of haemorrhage, have been published, so this might have led to changes in policies. On the other hand, a review by the International Confederation of Midwives and the International Federation of Gynaecology and Obstetrics has suggested that as far as the management of the third stage is concerned, the main advantages of misoprostol are in resource-poor countries where it is difficult to maintain oxytocin at the required temperature.

Despite these limitations, this survey has provided new information about differences in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe.

This project did not attempt to fill the gap in information about the relationship between units’ stated policies and their actual practice. A comparison of actual practice in units with the same stated policy was undertaken in 1999 in an international survey. This observed practice in the management of the third stage of labour in approximately 30 successive vaginal deliveries in 15 university-based obstetric centres with policies of active management of the third stage in two high-income and 13 low-income countries. It found considerable variations within and between units in the use of active management. This suggests that if there were guidelines for management, they were not clearly implemented, although compared with Europe, other issues may be involved, notably the availability of oxytocic drugs. Nevertheless, the existence of guidelines can affect practice, especially if practice is audited.

Conclusions

Considerable differences in policies for managing the third stage of labour were observed both between and within countries. For policies which were widespread, notably cutting and clamping the cord and use of uterotonics, there were differences in timing and use of pharmacological agents. There were greater similarities in policies for the immediate management of postpartum haemorrhage, but considerable differences between and within countries in the choice of pharmacological agents. Further research is needed to ascertain whether policies are being translated into practice and assess their associations with the incidence and consequences of postpartum haemorrhage.

Contribution to authorship

S.A. initiated the collaborative project. C.W., A.M., C.D-T., W-H.Z., S.A., P.B., M.-H.B.C., W.P. and V.C. participated in the design of the survey and the questionnaire. J.vR., I.B., M.K., D.A-de-C., R.E., L.M.C., B.S-P., and C.T. commented on the design of the survey and the questionnaire. C.W., A.M., C.D-T., W-H.Z., S.A., M.-H.B.C., W.P., V.C., J.vR., I.B., M.K., D.A-de-C., R.E., L.M.C., B.S-P. and C.T. were involved in undertaking the survey in their countries and J.L-R. participated in the survey. C.W. and A.M. cleaned and analysed the data and drafted the paper. All the authors took part in the revision of the paper and have seen and approved the final version. None have any conflicts of interest.

EUPHRATES steering group

S.A. (Obstetrician, Epidemiologist), W-H.Z. (Epidemiologist), M.-H.B.C. (Epidemiologist), G.B. (Epidemiologist), C.D-T. (Epidemiologist), A.M. (Epidemiologist, Statistician), W.P. (Obstetrician), V.C. (Obstetrician), P.B. (Obstetrician, Epidemiologist) and C.W. (Midwife).
Acknowledgements

The project was funded by the European Union under Framework 5. We thank our colleagues who contributed to the work of the survey. In the UK, Hazel Ashurst played a major role in cleaning the data and preparing the data for analysis, and Kelly Rowson, Carol van Zyl and Rahel Uddin entered the data from all the participating countries. Others played an essential part in running the survey in their own countries. They include Fidelma Kavenagh (Ireland), Myriam Loubria (Belgium), Sophie Gouvaert (France), Judit Walczné Grof (Hungary), Maria Pompea Schiavelli (Italy), Paulo Sousa (Portugal) and Sonia Pisa (Spain). Kathy Herschderfer did the survey among midwives in the Netherlands, Bente Rønnes (Norway) and Carsten Henriques did the survey in Denmark. We thank Gerard Bréart (France), István Szabó, Jenő Egyed, János Herczeg (Hungary), Wolfgang Holzgreve, Irene Hösl and Olivier Iron (Switzerland) for their scientific advice and support.

References

1 Zhang W-H, Alexander S, Bouvier-Colle M-H, Macfarlane A; the MOMS-B Group. Incidence of severe pre-eclampsia, postpartum haemorrhage as a surrogate marker for severe maternal morbidity in a European population-based study: the MOMS-B survey. BJOG 2005;102:89–96.

2 Brace V, Penney G, Hall M. Quantifying severe maternal morbidity: a Scottish population study. BJOG 2004;111:481–4.

3 Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ 2001;322:1089–93.

4 Bouvier-Colle MH, Ould EJ, Varnoux N, Goffinet F, Alexander S, Bayoumeu F, et al. Evaluation of the quality of care for severe obstetrical haemorrhage in three French regions. BJOG 2001;108:898–903.

5 The EUPHRATES* Group. European Consensus on Prevention and Management of Post Partum Haemorrhage, 2005. [www.euphrates.insERM.fr/euphrates.nsf/AllDocumentsByUNID/95A14F46F3152A6C125707400485AED?OpenDocument&l=3.1]. Accessed 25 March 2007.

6 Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour (Cochrane Review). Cochrane Database Syst Rev 2000;CD000007. DOI: 10.1002/14651858.CD000007.

7 McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004; CD000201. DOI: 10.1002/14651858.CD000201.pub2.

8 Cotter A, Ness A, Tolosa J. Prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev 2001;CD001808. DOI: 10.1002/14651858.CD001808.

9 Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for prevention of postpartum haemorrhage. Cochrane Database Syst Rev 2004; CD000494. DOI: 10.1002/14651858.CD000494.pub2.

10 McDonald SJ, Abbott JM. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes (Protocol). Cochrane Database Syst Rev 2003; CD004074. DOI: 10.1002/14651858.CD004074.

11 Huh WK, Chelmow D, Malone FD. A double blinded, randomized controlled trial of oxytocin at the beginning versus the end of the third stage of labor for prevention postpartum hemorrhage. Gynecol Obstet Invest 2004;58:72–6.

12 Jackson KW Jr, Alibert JR, Schemmer GK, Elliot M, Humphrey A, Taylor J. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol 2001;185:873–7.

13 Soltani H, Dickinson F, Symonds I. Placental cord drainage after spontaneous vaginal delivery as part of the management of the third stage of labour. Cochrane Database Syst Rev 2005; CD004665. DOI: 10.1002/14651858.CD004665.pub2.

14 Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev 2003; CD003249. DOI: 10.1002/14651858.CD003249.

15 Mousa HA, Alfirevic Z. Major postpartum hemorrhage: survey of maternity units in the United Kingdom. Acta Obstet Gynecol Scand 2002;81:727–30.

16 American Academy of Family Physicians. ALSO Instructors Manual. University of Wisconsin, 2004.

17 Ndala R. Cephalopelvic disproportion, obstructed labour and other obstetric emergencies. In: Stable D, Rankin J, editors. Physiology in Childbearing, 2nd edn. London: Elsevier; 2005. pp. 565–74.

18 Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004–2006. Int J Gynaecol Obstet 2006;94:243–53.

19 Festin MR, Lumbignanon P, Tolosa JE, Finney KA, Ba-Thike K, Chipato T, et al. International survey on variations in practice of the management of the third stage of labour. Bull World Health Organ 2003;81:286–91.

20 Alfirevic Z, Edwards G, Platt MJ. The impact of delivery suite guidelines in the intrapartum care in “standard primigravida”. Eur J Obstet Gynecol Reprod Biol 2004;115:28–31.

21 Penney G, Adamson L, Kerghan D. Scottish Audit of Severe Maternal Morbidity. Second Annual Report 2004. Aberdeen: SPCCERCH, 2005.